Celltrion announced on the 29th that it has been selected as the preferred negotiation partner for the acquisition of a corporation with a raw material pharmaceutical production facility in the United States, having concluded a exclusive negotiation commitment. The name of the target corporation was not disclosed.
Previously, Celltrion has been pursuing the acquisition to mitigate tariff risks arising from exports to the United States and secure cost competitiveness through the establishment of a local production system.
Celltrion stated that it will conduct a definitive due diligence on the U.S. local factory owned by the target corporation and decide whether to enter into the main contract based on the results of the due diligence. It plans to finalize the acquisition process within the year when the main contract is signed.